Fluidic Analytics reels in $31M for development of its protein-characterizing tools

Illustration of three DNA helices
U.K.-based startup Fluidic Analytics reeled in $31 million in a round of fundraising to support the development of its protein-characterizing tools. (Darwin Laganzon)

U.K.-based startup Fluidic Analytics reeled in $31 million in a round of fundraising to support the development of its protein-characterizing tools designed to better understand the biology of conditions like Alzheimer’s disease as well as the interaction between drugs and their targets.

The funding round was led by Draper Esprit. Delin Ventures, BGF, IQ Capital and Amadeus Capital Partners also participated in the round.

Fluidic’s products are based on a proprietary platform developed at the University of Cambridge that allows researchers to delve deeper into how proteins fold, aggregate and interact “by characterizing them in solution—precisely as they exist in the body,” the company said in a release.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“This financing will power the global commercial launch of our Fluidity One system and enable our team to bring our next two lab-tools products to market,” Andrew Lynn, Fluidic’s chief executive, said in a statement. “It will also allow us to advance a number of high-potential clinical applications that could help us make an even bigger impact on the world.”

The way proteins behave is important to understanding how diseases develop, identifying the way drugs interact with their targets, and developing new methods for matching the right treatment to the right patient at the most optimum time, the company said.

Suggested Articles

WIRB-Copernicus Group has added two new executives to its roster as it expands its Global Research Network of investigative sites.

Incoming FDA Commissioner Ned Sharpless used his first official talk to ensure we all know he’s not looking to tear up Scott Gottlieb’s legacy.

Charles River Labs and the CHDI Foundation have signed a five-year extension for their Huntington’s disease work.